Redirecting to https://www.mrknewsroom.com/newsroom/news-releases/news-details/2020/FDA-Approves-Mercks-KEYTRUDA-pembrolizumab-for-First-Line-Treatment-of-Patients-With-Unresectable-or-Metastatic-MSI-H-or-dMMR-Colorectal-Cancer/default.aspx...

Click here if your browser doesn't automatically take you to this page.